Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Simulations Plus Inc SLP

Healthcare Medical Devices
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus... see more

Recent & Breaking News (NDAQ:SLP)

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer

Business Wire July 21, 2022

Simulations Plus Realizes Early Success with its Concierge Program

Business Wire July 14, 2022

Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results

Business Wire July 6, 2022

Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop

Business Wire June 30, 2022

Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment

Business Wire June 23, 2022

Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call

Business Wire June 21, 2022

DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine

Business Wire June 16, 2022

Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)

Business Wire May 26, 2022

U.S. FDA Renews Annual DILIsym Software Licenses for 2022

Business Wire May 5, 2022

Simulations Plus Successfully Delivers FDA-Funded Project

Business Wire April 28, 2022

Simulations Plus Enters New Collaboration to Advance DDDPlus(TM) Software

Business Wire April 21, 2022

Simulations Plus to Present at the Berenberg Discover AI Seminar

Business Wire April 19, 2022

Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results

Business Wire April 6, 2022

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym(TM) Macromolecule Safety Software

Business Wire March 29, 2022

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference

Business Wire March 24, 2022

Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call

Business Wire March 22, 2022

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders

Business Wire March 17, 2022

Simulations Plus Releases MembranePlus 3.0

Business Wire March 10, 2022

Simulations Plus to Present at Oppenheimer Annual Healthcare Conference

Business Wire March 8, 2022

Simulations Plus to Present at Raymond James Institutional Investors Conference

Business Wire March 2, 2022